Dr Reddy's Laboratories Ltd reported a weaker-than-expected March quarter performance, weighed down by lower sales in North America and the impact of g-Revlimid-related adjustments. Brokerages largely ...

Analysts have raised concerns around Dr Reddy’s Laboratories’ growth outlook after the pharmaceutical company posted a weaker-than-expected March quarter (Q4FY26) result. They believe a sharp decline ...

Pharma major Dr. Reddy’s Laboratories reported consolidated net profit slumped to ₹221.3 crore for the March quarter compared to ₹1,586.7 crore a year earlier on the back of lower sales and multiple ...

Dr Reddy shares: Shares of pharma major Dr Reddy's Laboratories swung between gains and losses in morning deals on the BSE on Wednesday, 13 May, a day after reporting a 86% year-on-year (YoY) drop in ...

Shares of Dr Reddy's Laboratories will be in focus on Wednesday, May 13, after the pharmaceutical major reported a weak March quarter performance, impacted by lower sales of Lenalidomide, the generic ...

Dr Reddy's Q4 net profit dropped 86% YoY to Rs 221 crore from Rs 1,593 crore Revenue declined 11.5% YoY to Rs 7,546 crore, missing analyst expectations EBITDA fell 60.4% YoY to Rs 981 crore with ...

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer ...

Hyderabad: Lower lenalidomide sales (Revlimid) in the North America markets dragged Dr Reddy’s Labs’ consolidated net profit by 86% for the fourth quarter ended March 31, 2026, to nearly Rs 221 crore ...

Dr Reddy's Laboratories Ltd on Tuesday reported a sharp decline in its consolidated net profit for the March-ended quarter, falling 86 per cent year-on-year (YoY) to Rs 221 crore compared with Rs ...

Dr Reddy's Laboratories (DRL) posted a sharp decline in net profit for the January–March quarter (Q4FY26), reporting earnings of ₹220 crore compared with ₹1,587.3 crore in the same period last year.

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday reported an 86 per cent dip in consolidated profit after tax at Rs 221.3 crore in the fourth quarter ended March 31, 2026 hit by lower generics sales ...

Dr Reddy's Q4 profit slumps 86% due to cancer therapy impairment Revenue falls 11.5% amid US pricing pressure and competition Lenalidomide sales drop; semaglutide eyed for future growth Drugmaker Dr ...